Absence of evidence that Slc12a8 encodes a nicotinamide mononucleotide transporter

Plain-language summary

Published 2019 in Nat Metab, this work by Schmidt MS and collaborators tackles a specific question within science-focused NMN/NAD+ research.

Key findings reported by the authors

• Mechanistic study in Nat Metab (2019) on NAD+/sirtuin/longevity biology
• Adds to the foundational literature underlying NMN supplementation rationale
• First author: Schmidt MS

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the limited end of the evidence spectrum. Limited-tier evidence (mouse, in-vitro, or single small pilot) is hypothesis-generating only; do not extrapolate dosing or efficacy claims to humans without supporting replication. Findings here are most directly relevant to science decisions. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.